Skip to content
Shares in AstraZeneca (AZN) dropped 3.5% even after early-stage human trial data from its Covid-19 vaccine candidate showed “robust” immune responses.The stock declined to $58.96 in afternoon market trading. Interim data results from the ongoing Phase I/II trial of the potential coronavirus vaccine, also known as AZD1222, which AstraZeneca is developing with Oxford University, showed “strong” antibody and immune T-cell responses.“While there is more work to be done, today’s data increases our confidence that the vaccine will work and allows us to continue our plans to manufacture the vaccine at scale for broad and equitable access around the world,” said Mene Pangalos, Executive VP of BioPharmaceuticals R&D.The results demonstrated that a single dose of AZD1222 resulted in a four-fold increase in antibodies to the SARS-CoV-2 virus spike protein in 95% of participants one month after injection. In all participants, a T-cell response was induced, peaking by day 14, and maintained two...
Isuzu Commercial Truck of America, distributor of low-cab-forward trucks, welcomed its newest dealership, in Wyoming, giving the company dealerships in all 50 states. ...
How far off is StoneCo Ltd. (NASDAQ:STNE) from its intrinsic value? Using the most recent financial data, we'll take a......
Over the last few years – and certainly since the March crash - tech stocks have been on a tear. However, veteran tech giant IBM (IBM) has found it difficult to keep up, and has lagged behind the whole market. Yet, with F2Q earnings due today after market close, could sentiment be changing?With the Street calling for a year-over-year drop of 35% to revenue of $17.7 billion and EPS to decline by 8% to $2.07, Merrill Lynch analyst Wamsi Mohan argues the low expectations could provide IBM with a minor victory when it releases its quarterly statement this evening.Mohan said, “We expect IBM to report a small beat relative to a very depressed consensus in the wake of COVID-19. Consensus is modeling a flat q/q trend vs normally up mid-single digits. However, while near term trends will be scrutinized, we think the more important catalyst will be an update from CEO Arvind...
Columbia University's Dr. Bernard Chang joins Yahoo Finance’s Zack Guzman to discus the recent coronavirus developments as cases surge in states like Florida and California....
The markets face two big risks amid the COVID-19 pandemic, says Tom Essaye, founder of the Sevens Report Research....
When more than 60% of delivery crashes happen in the parking lot, it's time to take action. Follow these seven tips to increase driver safety in parking lots. ...
